Treatment of myelodysplastic syndromes with 5-azacytidine
β Scribed by Jeffrey Gryn; Zella R. Zeigler; Richard K. Shadduck; John Lister; Jane M. Raymond; Ibrahim Sbeitan; Charles Srodes; Dennis Meisner; Cynthia Evans
- Book ID
- 108403229
- Publisher
- Elsevier Science
- Year
- 2002
- Tongue
- English
- Weight
- 45 KB
- Volume
- 26
- Category
- Article
- ISSN
- 0145-2126
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract ## BACKGROUND. The treatment of myelodysplastic syndromes (MDS) remains a challenge to the clinician despite recent advances. Many patients will either not respond or will have only limited and/or brief responses to singleβagent therapy. Eventually, 30% of patients with MDS will progre
T he article by Ferrara et al. 1 in this issue of Cancer describes the treatment of patients with poor prognosis myelodysplastic syndromes (MDS) using intensive remission induction chemotherapy followed by peripheral blood stem cell transplantation for patients age Ο½ 60 years. Thirty-two patients wi